Acute Lymphoblastic Leukemia ,Lymphomas, Acute Myeloid Leukemia, ALL, Aml, Ewing Sarcoma, Medulloblastoma, Osteosarcoma, Rhabdomyosarcoma, Sarcoma
Conditions
Keywords
Cancer Survivorship, Adolescent and Young Adult Cancer, Late Effects of Cancer Treatment, Hodgkin and mature B-cell Lymphomas, Acute Lymphoblastic Leukemia/Lymphoma, Sarcoma, Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, Acute Myeloid Leukemia, Aml, ALL, Medulloblastoma
Brief summary
This study aims to design and test a novel, personalized digital intervention-my.naviGATE-for adolescent and young adults (AYA) with cancer. my.naviGATE is a mobile app that provides personalized survivorship education, access to virtual peer navigation, and responsive participant-reported outcomes (PROs).
Detailed description
This multi-center, pilot study aims to design and test a novel, personalized digital intervention-my.naviGATE-for adolescent and young adults (AYA) with cancer. My.naviGATE is a mobile app that provides personalized survivorship education, access to virtual peer navigation, and responsive participant-reported outcomes (PROs). Participants in this research study will be randomized into 1 of 2 study groups: my.naviGATE Group versus Usual Care Group. Randomization means a participant is placed into a study group by chance. The research study procedures include questionnaires or surveys, use of the mobile app for those randomized to the intervention, and qualitative interviews with study personnel for a subset of participants. It is expected about 143 people will participate in this research study. The Hyundai Hope On Wheels Foundation is supporting this research study by providing funding.
Interventions
BEHAVIORALmy.naviGATE Digital Tool
: A HIPAA-compliant digital health intervention in the form of a mobile application that provides personalized cancer survivorship education based on individual treatment regimens, virtual visits with trained peer navigators, and collection questionnaires/survey responses.
Sponsors
Dana-Farber Cancer Institute
Hyundai Hope On Wheels
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
15 Years to 24 Years
Healthy volunteers
No
Inclusion criteria
* Patients aged 15-24 who are currently undergoing cancer treatment at one of the three participating sites: DFCI, CNH, or RPOCH. * Patients must have initiated and be actively receiving cancer directed therapy for a newly diagnosed cancer. * Patients must be actively receiving cancer directed therapy, between the time of diagnosis and end of therapy for the following diagnoses: 1) Sarcomas: including osteosarcoma, Ewing sarcoma, and rhabdomyosarcoma; 2) Acute Myeloid Leukemia (AML); 3) Acute Lymphoblastic Leukemia/Lymphoma (ALL); 4) Hodgkin and mature B-cell Lymphomas; and 5) Medulloblastoma. * Patients whose treatment includes alkylators, anthracyclines, and/or radiation. Inclusion of Children: • This study is designed to keep AYAs aged 15-24 engaged in cancer survivorship care and therefore a subset of participants will be \<18 years of age. The rationale for inclusion of children in this study is that AYA cancer survivors are particularly vulnerable to loss to follow-up and consequently lack of risk-based survivorship care, resulting in increased risk for preventable toxicity. Many existing interventions to improve engagement in survivorship screening and care are introduced after treatment completion and in long-term survivorship. Yet, for patients who are unaware of their late effect risks, and/or those who move frequently and are lost to follow-up, this may be too late. This study is designed to improve awareness of and engagement in risk-informed survivorship care for AYAs. This study presents no more than minimal risk to participants.
Exclusion criteria
* Patients who are unwilling to give informed consent or assent to participate will be excluded. For patients under 18, patients whose guardians do not give informed consent will be excluded. * Patients with no chance of cure as identified by the AYA's physician, will be excluded given that issues of survivorship are not relevant and may be distressing to this population. Similarly, patients with relapsed or refractory disease will also be excluded. * Patients who are non-English-speaking and -reading will be excluded as the digital tool is being developed initially in English. * We will seek physician permission before offering enrollment to patients. If the provider team requests that the patient not be approached to participate, the patient will be excluded.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Patient Activation Measure (PAM)-13 Score from Baseline to 6 Months Post-EOT | Assessed at baseline, 1-month post EOT (+2 months) and 6-months post EOT (+2 months) | The Patient Activation Measure (PAM-13) is a validated, self-administered questionnaire assessing knowledge, skills, and confidence for self health-management. It has 13 items with a standardized score from 1-100 derived from 4-point Likert scale answer choices ranging from "Disagree Strongly" to "Agree Strongly;" a higher standardized score represents greater activation. |
| Application (App) Feasibility Rate (Intervention Group) | Assessed at 1-month post EOT (+2 months) and 6-months post EOT (+2 months) | App feasibility rate is the proportion of participants in the intervention group ever using the my.naviGATE app. Usage metrics are collected through the app development platform. |
| Application (App) Acceptability Rate (Intervention Group) | Assessed at 1-month post EOT (+2 months) and 6-months post EOT (+2 months) | App acceptability will be assessed in the intervention group with an adapted acceptability electronic (E)-scale for web-based PROs in cancer care. Acceptability rate is the proportion of patients achieving acceptability on the 3-item scale, each using the 5-point Likert scale (1=lowest acceptability/not acceptable to 5 highest acceptability). The score ranges from 3-15 points and a score of 12 or higher indicates acceptability. (Tariman et al. Appl Nurs Res. 2011) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Patient Assessment of Cancer Communication Experiences (PACE) Scale Score (Treatment Completed Set) at 6 Months Post-EOT | Assessed at 1-month post EOT (+2 months) and 6-months post EOT (+2 months) | The PACE Scale (treatment completed set) is a 6-item questionnaire assessing communication and support experiences during and after cancer treatment. Questions are rated on a Likert-style scale ranging from "Never" to "Always" or "Poor" to "Excellent." Across a sample of patients with a variety of cancers, 70% rated post-cancer treatment communication as excellent. |
| Preparedness for Survivorship Score at 6 Months Post-EOT | Assessed at 1-month post EOT (+2 months) and 6-months post EOT (+2 months) | Preparedness for survivorship is measured on a 10-item scale with response items ranging from "strongly agree" (4) to "strongly disagree" (1) or "strongly satisfied" (5) to "not at all satisfied" (1); higher mean composite scores suggests increased perceived preparedness for survivorship. |
| Self-Efficacy Score at 6 Months Post-EOT | Assessed at 1-month post EOT (+2 months) and 6-months post EOT (+2 months) | Self-efficacy for late effect and survivorship care planning will be measured by two adapted 3-item self-efficacy scales. The mean of the Late Effects Self-Efficacy scale is 3.3 (SD=1.1), and the mean of the Survivorship Care Planning Self-Efficacy scale is 3.9 (SD=1.2). Items are rated from 1=not confident to 5=extremely confident; higher scores suggest greater perceived self-efficacy. |
| Patient-Reported Outcomes Measurement Information System (PROMIS) Global Health Score Change at 6 Months Post-EOT | Assessed at 1-month post EOT (+2 months) and 6-months post EOT (+2 months) | The 9-item PROMIS Pediatric Scale for Global Health (participant age \<18) and 10-item PROMIS Scale for Global Health (participant age 18+) are validated measures of health-related quality of life (HRQoL). Responses are scored on a scale of 1-5, and the total score is converted to a T-score with a mean of 50 and a standard deviation (SD) fixed at 10. Higher scores suggest better perceived HRQoL. The final question on the adult version is scored 1-10. |
Countries
United States
Contacts
CONTACTKatie Greenzang, MD
PRINCIPAL_INVESTIGATORKatie Greenzang, MD
Dana-Farber Cancer Institute
Outcome results
None listed